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Abstract Background This study describes the barriers
to effective and timely LTBI treatment encountered in a
research study on INH adherence in Latino adolescents.
Method Participant study logs were reviewed, results of
continuing medical education pretests for medical pro-
viders were examined, and participating medical facilities
were contacted in order to construct a proﬁle of multi-
level barriers to LTBI treatment. Results A total of 285
TST positive Latino (96%) high school students were
recruited into the trial. We encountered a lack of under-
standing of the gravity of tuberculosis infection among
both the public and providers of health care. Parents and
adolescents cited competing priorities, transportation
problems and ﬁnancial constraints as reasons for
non-compliance. Discussion Improved education of the
public and physicians is needed regarding the gravity of
the disease and the value of treatment, as well as public
and ﬁnancial support for LTBI treatment by both the
government and the medical community.
Keywords Latent tuberculosis infection  Compliance 
Latino adolescents  Barriers to treatment
Background
Tuberculosis (TB) continues to be a worldwide cause of
morbidity and mortality, with an estimated 8.8 million new
cases in 2005 [1]. The emergence of multi-drug resistant TB
(MDRTB) and extremely drug resistant TB (XDRTB), and
theassociationofTBwithHIVhavekeptTBintheforefront
of public health concerns [2]. Tuberculosis infection (LTBI)
is present in one-third of the world’s population [3]. LTBI,
from which the majority of disease is derived, proceeds to
activediseaseinapproximately4–13% ofTB-infectedHIV-
negative individuals within 5 years [4], and at a rate of 10%
per year in TB-infected HIV-positive individuals [5].
Approximately 5% (15 million individuals) of the U.S.
population has LTBI; active TB was reported in approxi-
mately 14,000 individuals in 2005, and is most prevalent in
low income and immigrant populations [6].
TheAdvisoryCouncilfortheEliminationofTuberculosis
(ACET) recommends expanded ‘‘testing and treatment of
LTBI among targeted populations’’ in the efforts to meet TB
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DOI 10.1007/s10903-008-9216-5elimination goals [7]. The most commonly recommended
treatmentforLTBIintheUSisa9 monthcourseofisoniazid
(INH), which is over 90% efﬁcacious in preventing pro-
gression, even in individuals with variable compliance [8].
Treatment of children and adolescents is felt to be particu-
larly important because of their increased risk of progression
toactiveTB,expectedgreaternumberofyearsofrisk,aswell
as the safety of treatment [8, 9].
Treatment of active TB has been compromised by poor
patient compliance, which is well documented. Directly
Observed Therapy (DOT) is now the community standard
for active disease treatment [10–16]. Compliance with
LTBI treatment is also problematic; in the US, completion
of even a minimum of 6 months of LTBI treatment by
infected adolescents is estimated at only 33–74% [9, 17–
19]. The Healthy People 2010 treatment goal is 85% [20].
The purpose of this paper is to describe the barriers to
effective and timely LTBI treatment encountered in a
research study on isoniazid adherence in adolescents.
Methods
Thisreportderivesfroma5-yearNIH-fundedstudydesigned
to evaluate the effectiveness of peer counseling combined
with parent training to increase isoniazid adherence in ado-
lescents with LTBI. For the present report, participant study
logs (which included records of all participant activities)
were reviewed, results of continuing medical education
(CME) course pre-tests for medical providers were exam-
ined, and participating medical facilities were contacted in
ordertoconstructaproﬁleofthemulti-levelbarrierstoLTBI
treatment. Barriers related to participants, parents, medical
providers, and funding were examined.
Seven high schools in San Diego County, with student
populations between 13 and 21, were targeted for screen-
ing. All of these schools are located within 15 miles of the
Mexican border and thus have a high percentage of Latino
and immigrant youth. Students that screened positive
([10 mm) and their parents were invited to attend infor-
mational sessions on LTBI, which were provided at their
child’s school, and included education about TB, treatment,
transmission, and the research project.
Students found to be TST positive and one parent were
offered enrollment in the adherence trial; conﬁrmation was
obtained before screening and before enrollment that they
had not been previously treated for TB or LTBI. Bilingual,
culturally competent staff completed all of the participant
recruitment. All TST positive participants were offered free
chest X-rays (CXRs), help ﬁnding a medical home if
needed, and help scheduling and attending their ﬁrst
medical appointment. The purpose of the CXR was clearly
explained to the participating parent and student. One
parent and participants were administered a baseline
questionnaire after enrollment in the study.
Prior to a three-lecture CME course, clinicians com-
pleted a 40-question pre-test to assess LTBI knowledge.
The questions included topics on skin tests, medication and
duration of treatment, dosages, side effects, and co-infec-
tion with HIV. For the purposes of the CME testing, the
CME content, and this study, the following LTBI treatment
protocols were recommended (based on the CDC recom-
mendations for LTBI [21]): 9 months of isoniazid, 10–
20 mg/kg up to 300 mg/day; baseline screening by history
for liver disease and alcohol use; baseline liver function
tests only for those patients with a positive history of liver
disease or alcohol abuse; monthly visits for review of side
effects with face-to-face encounters; only 1 month of
medication given each visit; baseline patient education of
side effects and instructions to return sooner than 1 month
if side effects develop; 9 months of isoniazid must be taken
within a 12-month period (i.e., short gaps do not require
restarting medications); B-6 supplementation when dietary
intake is not expected to meet the requirements.
Prior to the completion of the intervention, ﬁve of the
participating health centers were contacted to ascertain
protocols and practice of LTBI treatment. The health
centers reﬂected the care received by the participants: one
private practice, two community health centers, one mili-
tary health center (for dependents) and the County LTBI
clinic. A survey was done in person by a FIESTA staff
member (a registered nurse and MPH student) regarding
LTBI medications, dosages, length of treatment, follow-up,
and lab testing.
This study was approved by the Committee on Protec-
tion of Human Subjects of San Diego State University.
Results
Participants
Of the 285 TST positive youths recruited into the trial, the
mean age was 15.9 years (±1.2) (Table 1). Fifty percent
were females and 49% had no health insurance. Forty-ﬁve
percent were foreign born and 96% were Latino. The
majority of the participants (90%) spoke two languages,
Spanish and English, with Spanish being the primary lan-
guage for about 85%. Sixty-two percent were considered to
be bicultural using the Marin & Gamba acculturation scale
[22].
Parents
The majority of parents who participated were female
(86%), with most (80%) being the participant’s Mother
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123(Table 1). The mean age of the participating parent was
42.5 years (±7.8) and 44.0 years (±7.8) for the other
parent. The mean years of education for both parents was
over nine years (participating parent: M = 9.5, ±3.6; other
parent: M = 9.6, ±3.9). Ninety-six percent of both parents
were Latinos, with 89% of the participating parents born in
Mexico (93% were foreign born) and 87% of the other
parents born in Mexico (90% were foreign born). Sixty-six
percent of the participating parents spoke only one lan-
guage with the primary language being Spanish for 83%,
while 60% of the other parent spoke two languages, again
with Spanish being the primary language for the majority,
89%. The median income for the previous year was
$\10,000 for the participating parent and $20,000–29,000
for the other parent, with the median for the household
being $20,000–29,000. Forty-ﬁve percent reported not
having any medical insurance.
Participant Barriers
A diagnosis of LTBI involves a positive TST and a nega-
tive CXR. X-rays are required to rule out active TB.
Participants were encouraged to obtain a CXR as soon as
possible, and staff maintained constant contact to monitor
their progress to this end. Participants were contacted four
to ﬁve times a week for a month, and then weekly until
they were on medications (isoniazid). Assistance was pro-
vided as necessary. Many participants required prompting
and assistance to obtain baseline X-rays, initiate treatment,
and maintain treatment. About 46% of participants required
assistance in receiving a CXR, requiring a mean of 1.5
contacts (range 0–14) in the form of telephone calls and/or
home visits by project staff. Almost 19% required a home
visit(s) to schedule the initial medical visit to get started on
isoniazid(meanof0.7,range 0–23)and58%requiredphone
call(s) (mean of 3.2, range 0–39). Home visits and phone
calls were used to provide additional patient/parent educa-
tion and to facilitate compliance with clinic appointments to
initiate isoniazid.
Once appointments were scheduled, compliance with
these medical visits was also a problem. Thirty-four par-
ticipants (12%) missed one or more initial clinic
appointments (range 0–6), and 15 (5%) required transpor-
tation by project staff. Continuing care was also an issue,
with ongoing prompting required to enhance compliance
with the follow-up clinic appointments.
Participants reported a general lack of knowledge of
LTBI and TB at the initial interview. Twenty-two percent
did not know that TB could be detected by a skin test; 15%
did not know that LTBI treatment reduces the risk of TB,
and 32% did not know that TB could be cured.
In addition to the routine continuity visits, some par-
ticipants reported symptoms compatible with isoniazid side
effects to our staff during intervention and measures visits,
which required study staff to facilitate getting participants
to their medical providers for unforeseen visits. Although
no true isoniazid side effects were detected by providers in
this study, the expenses for these visits were outside of the
routine LTBI care, and often involved blood tests, which
lead to ﬁnancial issues for the participants, and difﬁculty in
enforcing compliance with these visits.
Parental Barriers
The baseline questionnaire revealed a lack of parental
knowledge regarding LTBI and LTBI treatment. Twenty
percent of the participating parents did not know that LTBI
could be detected by a skin test and 13% did not know that
completing LTBI treatment greatly reduces risk of TB.
Thirty percent of parents did not feel that TB could be
cured, and 26% were ‘not worried when they found out
their child had a positive TST.’ Forty percent of parents did
Table 1 Baseline
characteristics and knowledge
of participants (adolescent and
parent)
Characteristic Adolescents Parents
Sample size 285 285
% female 50% 86% (80% mother)
% Latino 96% 96%
% foreign born 45% 93%
Spanish primary language 85% 89%
% with no health insurance 41.8% 45%
Median household income NA $20,000–29,000
% of respondents who selected the incorrect
response or ‘don’t know’
Did not know that TB can be detected by a skin test 22.5 7.1
Did not know that LTBI treatment reduces risk of TB 15.1 3.5
Did not feel that TB can be cured 32.6 15.8
Not worried when they found out they had a positive TST 26.7 NA
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123not think that positive TST reﬂected being ‘infected with
TB bacteria at some time in the past,’ while 14% thought it
was from ‘receiving BCG vaccine as a child,’ and 19%
attributed it to ‘scratching the site.’
Parents’ work conﬂicts and lack of transportation con-
tributed to the difﬁculties in scheduling appointments for
the CXR and isoniazid. This barrier was solved for those
adolescents with a means of independent transportation
through obtaining parental consent forms that permitted
LTBI treatment without their presence. Parents frequently
attributed lack of attendance to medical visits to costs to
see a provider, even the modest charges of community
health centers.
One parent’s concerns about potential side effects in
their child prompted cessation of LTBI treatment and
dropping out of the study.
Provider-Related Barriers
The providers in the participating San Diego health centers
were given the opportunity to obtain 3 h of CME credit for
attending on-site LTBI in-services. Eighty-ﬁve physicians
and mid-level practitioners were offered CME. Of these, 24
(28%) participated, yet just 17 (20%) providers took the
CME pre-test required to obtain CME credit. Only 13
(77%) of the 17 completed pre-tests received a passing
grade (60% correct). The post-tests were completed by 9 of
the 17 providers, with 78% receiving a passing grade.
During the in-services, we also encountered resistance to
the CDC recommendations for monthly visits to evaluate
persons treated with isoniazid for side effects. Some pro-
viders stated that ‘their patients would not return monthly,’
and, for that reason, they planned to continue prescribing/
dispensing 2–3 months or more of medication at a time.
Five of the participating health centers completed the
survey to assess their LTBI standards of care. The survey
results were compared with the CDC’s guidelines for LTBI
treatment. Respondents for the participating health centers
included one medical director (physician), one staff phy-
sician, one RN, one public health nurse, and one medical
assistant. Four of the ﬁve clinics correctly identiﬁed the
dosage of isoniazid for daily regimes, with four of the
clinics correctly identifying 300 mg as the maximum
dosage for daily regimes. Three of the clinics correctly
cited 9 months of treatment as the correct length of treat-
ment for daily treatment with isoniazid; three also had
protocols to see patients monthly. The other two clinics
saw patients at initial visit only (one) and initial visit and
ﬁnal visit (one).
Of the participants who were given only 1 month of
isoniazid at a time, 120/156 (77%) came back for the
1 month follow up, and 140/156 (90%) came back for at
least one more visit. However, of the participants who were
given more than 1 month, only 9/19 (47%) came back
before their prescription ran out, and 13/19 (68%) ever
came back. For those participants whose charts did not
indicate the number of pills given, only 17/48 (35%) ever
had another visit.
Funding-Related Barriers
Until 2004, the County of San Diego was able to provide
public funded care for LTBI, either through direct services,
or through subcontracts with the community health clinic
(CHC) system. However, due to shrinking public health
funds in general as well as those for TB control, CDC’s
priorities narrowed to active tuberculosis treatment and
contact tracing and care. The County is now only able to
provide limited direct LTBI care, and does no subcon-
tracting. Per parental reports, even the modest charges of
the participating CHCs for LTBI treatment were prohibi-
tive for some participants. Similarly, providing care at
discounted rates that families could afford was prohibitive
for many of the community clinics to afford.
Participant Feedback About Clinical Care
Participants provided study staff feedback on their contacts
with physicians when attempting to get started on isonia-
zid, reﬂecting misinformation and mistreatment. This
included inappropriate dosing, not scheduling monthly
visits, inappropriate length of treatment regimens, and
inappropriate staff and/or methods of obtaining medical
histories of possible side effects of isoniazid. Some par-
ticipants seeing providers in San Diego reported that they
were told: ‘‘Adolescents don’t need treatment for LTBI’’,
‘‘Only 6 months of treatment is needed,’’ ‘‘Isoniazid is too
toxic to use in adolescents.’’ Several participants seeing
providers in Tijuana heard: ‘‘The positive TST in Mexicans
is from BCG, and your child doesn’t need treatment’’ and
‘‘Don’t take medicine, just get a CXR every year.’’ This
type of misinformation contributed to refusal to enroll in
the study by at least 16 potential participants.
Additional problems were reported by parents and par-
ticipants regarding obtaining reﬁlls. In some cases, families
were told that medication was ready, but when they arrived
at the facility to pick it up, there was no prescription.
Patients attending facilities using a mail system, where
medication reﬁlls of isoniazid were mailed to the patient’s
home, reported never receiving the reﬁlls. Patients reported
sometimes being asked about side effects by a nurse, a
medical assistant, a receptionist, or not at all. This ques-
tioning sometimes took place in person, and sometimes by
phone.
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Successful treatment of LTBI in adolescents requires tar-
geted screening, appropriate initiation of treatment, and
compliance with the entire treatment regimen [18, 23, 24].
The results of this study are consistent with barriers iden-
tiﬁed in other studies, including a serious lack of
understanding of the gravity of LTBI amongst both the
public and providers of health care [25, 26]. Generally,
providers demonstrated a lack of basic knowledge of TB on
written tests and in practice. Those providers who did not
follow CDC guidelines on number of pills to give at a time
(1 month) were less likely to see their patients before the
medication was ﬁnished, and less likely to ever see the
patients, with implications for both compliance and
screening for side effects.
This is also consistent with other studies demonstrating
gaps between current CDC guidelines for LTBI treatment,
and physicians’ attitudes and practice in the community
[27]. This included misinformation regarding treatment of
LTBI in patients TST positive, who had received BCG,
despite CDC recommendations to ignore the BCG history
[21]. Furthermore, we encountered a lack of interest from
the parents and adolescents as evidenced by the difﬁculty
in getting adolescents screened and enrolled. The efforts
expended to get these adolescents into care, with multiple
attempts required, are completely unrealistic for non-
research settings in absence of substantial ﬁnancial support
not now available.
One practice we put into place for study participants was
to request that parents sign consent forms for their child’s
LTBI treatment without the parents being physically
present at the time of the visit. This is an option that may
be useful for older adolescents in LTBI care in community
settings. System-wide solutions to barriers include
streamlining LTBI follow-up visits, using dedicated LTBI
staff, and having consistent methodologies for screening
for side effects and reﬁlling medicine. These might have
eliminated much of the frustration reported by our partic-
ipants in obtaining reﬁlls, and the frustrations clinic
personnel encountered when patients showed for TB care
but were not in the appointment system or when patients
did not show when they were scheduled.
National funding for LTBI treatment increased after the
2000 IOM report Ending Neglect [28], however the ﬁve
million dollars of designated funding was only available for
5 years (Dr. K. Moser, personal communication). The CDC
outlined recommendations for LTBI activities in their
‘‘CDC’s Response to ending neglect: The elimination of
tuberculosis in the US 2002’’ [29]. However, after 2004, the
Division of TB Elimination at the CDC prioritized other TB
control activities, including active disease, contact tracing,
research, genotyping, education centers, and others.
Currently no funding from the CDC speciﬁcally targets
screening and treatment for LTBI in the US. Yet, it has
been estimated that to eliminate active tuberculosis infec-
tion from a country the LTBI rates must be reduced to 1/
million population; current estimates based on NHANES
data show 4.3/million civilian, non-institutionalized popu-
lation as infected [30, 31]. Signiﬁcant efforts will be
required to achieve a 75% reduction in the prevalence of
untreated LTBI in the US.
This report has implications for the development of
strategies to promote LTBI screening and treatment. First,
the public needs to have a greater understanding of the
gravity of LTBI, and the implications for the future health
of infected individuals. Since a number of parents felt that
their child’s positive TST was due to receipt of BCG, the
availability of more accurate testing for LTBI, such as
Quantiferon, may be useful to overcome this barrier. This
is especially important in patients from Mexico and other
countries where BCG is commonly used.
Second, physicians need ongoing training to understand
and implement policies for screening and appropriate
treatment. Third, public funds are necessary to treat the
medically indigent infected with LTBI in order to improve
compliance and protect the whole population from TB
infection. Such treatment is necessary to reduce the
ongoing conversion to active TB and the continuing epi-
sodic epidemic outbreaks. With increasing frequency and
volume of travel world-wide, such outbreaks will become
more frequent and the spread across nations may take only
hours to occur. Effecting prevention of active TB by
treating those with LTBI remains the best means of
reducing the incidence of active disease.
Our ﬁndings suggest that the traditional clinical practice
procedures do not work well for TB prevention among
adolescents. Efforts should be undertaken to modify tra-
ditional patient provider examinations and counseling to
make treatment completion more likely while ensuring
satisfactory safety. This could be achieved by instituting
changes in the delivery of care for TB prevention. Among
these changes might be use of an ‘‘advice nurse’’ who
could track patients for follow-up contact/visits and new
prescriptions. This might involve face-to-face meetings on
some frequency less than monthly and telephone or email
contact to obtain information about possible side effects
and the need for more complete examination. Use of
incentives for preventive care should be considered key for
completing all prevention services and they can be justiﬁed
on the basis of protecting the public as much or more than
the patient. Providers should be compensated for TB pre-
vention services and held responsible for adhering to CDC
guidelines, even if such guidelines warrant greater ﬂexi-
bility to match both patient and provider needs for
convenient delivery of care. Experts in public health,
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123medical care and TB prevention in particular should con-
tribute to reﬁnements in current guidelines that allow
tailoring of medical monitoring that includes telemedicine
procedures and use of physician assistants to make the
overarching system more practical, effective and safe.
This report is limited by the observational nature of the
data. Due to the large Latino representation in this study, we
cannot generalize to other communities. Nevertheless, we
have no reason to believe that the ﬁndings are not represen-
tative of the attitudes and behavior of other parents and
physiciansofLTBIinfectedadolescentsincommunitieswith
similar demographics and with similar short falls in public
support for screening and preventive treatments for LTBI.
Tuberculosis continues to be a worldwide cause of
morbidity and mortality. The pool of infected individuals
with LTBI must be treated with appropriate therapeutics at
the recommended length of time to reduce the rates of
reactivation. Improved education of the public and physi-
cians is needed regarding the gravity of the disease and the
value of treatment, as well as public and ﬁnancial support
for LTBI treatment by both the government and the med-
ical community.
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